- Alibaba Health’s adjusted net income for FY 2024 is 1.44 billion yuan, showing a 91% year-over-year increase. This beats the estimate of 1.04 billion yuan.
- The company’s revenue for the fiscal year is 27.03 billion yuan, marking a 1% year-over-year rise. This is slightly below the estimated revenue of 28.08 billion yuan.
- Alibaba Health’s gross margin has improved to 21.8%, up from 21.3% the previous year, but fell short of the estimated 22.4% margin.
- The analyst ratings for Alibaba Health include 18 buys, 4 holds, and 1 sell.
A look at Alibaba Health Information Tec Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alibaba Health Information Technology Limited, an integrated healthcare information and content service provider, shows a promising long-term outlook according to Smartkarma Smart Scores. With a growth score of 5 and a resilience score of 5, the company demonstrates strong potential for future expansion and durability in the face of challenges. These high scores indicate a solid foundation for sustained success in the healthcare information sector.
In contrast, Alibaba Health Information Tec‘s value and dividend scores are lower at 2 and 1 respectively. This suggests that while the company may not be considered undervalued or a top dividend payer at the moment, its impressive growth and resilience scores overshadow these areas. Additionally, a momentum score of 2 indicates some fluctuations in short-term performance but does not diminish the overall positive outlook for Alibaba Health Information Technology Limited.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
